{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:35:40Z","timestamp":1768278940036,"version":"3.49.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-30705-y","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T14:45:42Z","timestamp":1765205142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overexpression of JMJD6 drives immune evasion via the BRD4\u2013IRF1\u2013PD-L1 axis and promotes malignancy in gastric cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Ryo","family":"Ishida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisuke","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Kiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Nishibeppu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masateru","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Arita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Kosuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Iehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Shiozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"30705_CR1","first-page":"11","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11\u201330 (2013).","journal-title":"CA Cancer J. Clin."},{"key":"30705_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ags3.12284","volume":"3","author":"S Komatsu","year":"2019","unstructured":"Komatsu, S. & Otsuji, E. Essential updates 2017\/2018: recent topics in the treatment and research of gastric cancer in Japan. Ann. Gastroenterol. Surg. 3, 581\u2013591 (2019).","journal-title":"Ann. Gastroenterol. Surg."},{"key":"30705_CR3","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"30705_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth, E. C. et al. Gastric cancer. Lancet 396, 635\u2013648 (2020).","journal-title":"Lancet"},{"key":"30705_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1535-6108(04)00033-9","volume":"5","author":"T Ushijima","year":"2004","unstructured":"Ushijima, T. & Sasako, M. Focus on gastric cancer. Cancer Cell. 5, 121\u2013125 (2004).","journal-title":"Cancer Cell."},{"key":"30705_CR6","first-page":"3845","volume":"54","author":"KF Becker","year":"1994","unstructured":"Becker, K. F. et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 54, 3845\u20133852 (1994).","journal-title":"Cancer Res."},{"key":"30705_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/(SICI)1096-9896(199604)178:4<475::AID-PATH517>3.0.CO;2-Q","volume":"178","author":"E Tahara","year":"1996","unstructured":"Tahara, E. & Yokozaki, H. The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J. Pathol. 178, 475\u2013476 (1996).","journal-title":"J. Pathol."},{"key":"30705_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0002-9440(10)64216-2","volume":"161","author":"JH Lee","year":"2002","unstructured":"Lee, J. H. et al. Inverse relationship between APC gene mutation in gastric adenomas and development of adenocarcinoma. Am. J. Pathol. 161, 611\u2013618 (2002).","journal-title":"Am. J. Pathol."},{"key":"30705_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/path.1170","volume":"198","author":"N Oue","year":"2002","unstructured":"Oue, N. et al. Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. J. Pathol. 198, 55\u201359 (2002).","journal-title":"J. Pathol."},{"key":"30705_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3748\/wjg.v9.i3.423","volume":"9","author":"Y Ding","year":"2003","unstructured":"Ding, Y. et al. Methylation and mutation analysis of p16 gene in gastric cancer. World J. Gastroenterol. 9, 423\u2013426 (2003).","journal-title":"World J. Gastroenterol."},{"key":"30705_CR11","first-page":"4257","volume":"59","author":"WS Park","year":"1999","unstructured":"Park, W. S. et al. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res. 59, 4257\u20134260 (1999).","journal-title":"Cancer Res."},{"key":"30705_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1747-1028-3-8","volume":"3","author":"JH Vissers","year":"2008","unstructured":"Vissers, J. H. et al. The many faces of ubiquitinated histone H2A: insights from the dubs. Cell. Div. 3, 8 (2008).","journal-title":"Cell. Div."},{"key":"30705_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S1470-2045(13)70587-4","volume":"15","author":"E Bachy","year":"2014","unstructured":"Bachy, E. & Coiffier, B. Anti-PD1 antibody: a new approach to treatment of lymphomas. Lancet Oncol. 15, 7\u20138 (2014).","journal-title":"Lancet Oncol."},{"key":"30705_CR14","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/1078-0432.CCR-12-2625","volume":"19","author":"EJ Lipson","year":"2013","unstructured":"Lipson, E. J. et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin. Cancer Res. 19, 462\u2013468 (2013).","journal-title":"Clin. Cancer Res."},{"key":"30705_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl. J. Med. 369, 134\u2013144 (2013).","journal-title":"N Engl. J. Med."},{"key":"30705_CR16","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-Positive Non-Small-Cell lung cancer. N Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"N Engl. J. Med."},{"key":"30705_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687\u2013697 (2010).","journal-title":"Lancet"},{"key":"30705_CR18","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang, Y. K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461\u20132471 (2017).","journal-title":"Lancet"},{"key":"30705_CR19","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro, K. et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 17, 717\u2013726 (2016).","journal-title":"Lancet Oncol."},{"key":"30705_CR20","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","volume":"36","author":"YY Janjigian","year":"2018","unstructured":"Janjigian, Y. Y. et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J. Clin. Oncol. 36, 2836\u20132844 (2018).","journal-title":"J. Clin. Oncol."},{"key":"30705_CR21","doi-asserted-by":"publisher","first-page":"e1581547","DOI":"10.1080\/2162402X.2019.1581547","volume":"8","author":"C Chen","year":"2019","unstructured":"Chen, C. et al. Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Oncoimmunology 8, e1581547 (2019).","journal-title":"Oncoimmunology"},{"key":"30705_CR22","first-page":"2170","volume":"58","author":"BC Bastian","year":"1998","unstructured":"Bastian, B. C. et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 58, 2170\u20132175 (1998).","journal-title":"Cancer Res."},{"key":"30705_CR23","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/sj.onc.1209166","volume":"25","author":"M Lin","year":"2006","unstructured":"Lin, M. et al. DNA copy number gains in head and neck squamous cell carcinoma. Oncogene 25, 1424\u20131433 (2006).","journal-title":"Oncogene"},{"key":"30705_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13148-016-0205-6","volume":"8","author":"O Aprelikova","year":"2016","unstructured":"Aprelikova, O., Chen, K. & Touny, E. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis. Clin. Epigenetics. 8, 38 (2016).","journal-title":"Clin. Epigenetics"},{"key":"30705_CR25","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1186\/s12885-020-07531-8","volume":"20","author":"A Biswas","year":"2020","unstructured":"Biswas, A. et al. Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer. BMC Cancer. 20, 1159 (2020).","journal-title":"BMC Cancer"},{"key":"30705_CR26","doi-asserted-by":"publisher","first-page":"e1001819","DOI":"10.1371\/journal.pbio.1001819","volume":"12","author":"F Wang","year":"2014","unstructured":"Wang, F. et al. JMJD6 promotes colon carcinogenesis through negative regulation of p53 by hydroxylation. PLoS Biol. 12, e1001819 (2014).","journal-title":"PLoS Biol."},{"key":"30705_CR27","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1007\/s13277-013-0789-9","volume":"34","author":"J Zhang","year":"2013","unstructured":"Zhang, J. et al. High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma. Tumour Biol. 34, 2397\u20132401 (2013).","journal-title":"Tumour Biol."},{"key":"30705_CR28","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1002\/ijc.31816","volume":"144","author":"J Wan","year":"2019","unstructured":"Wan, J. et al. JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4. Int. J. Cancer. 144, 2489\u20132500 (2019).","journal-title":"Int. J. Cancer"},{"key":"30705_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12943-017-0744-2","volume":"16","author":"X Liu","year":"2017","unstructured":"Liu, X. et al. JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component. Mol. Cancer. 16, 175 (2017).","journal-title":"Mol. Cancer"},{"key":"30705_CR30","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1186\/s12885-023-11171-z","volume":"23","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. JMJD6 functions as an oncogene and is associated with poor prognosis in esophageal squamous cell carcinoma. BMC Cancer. 23, 696 (2023).","journal-title":"BMC Cancer"},{"key":"30705_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.25259\/Cytojournal_230_2024","volume":"22","author":"X Zhang","year":"2025","unstructured":"Zhang, X. & Na, D. Jumonji domain-containing protein 6 promotes gastric cancer progression: modulating immune evasion through autophagy and oxidative stress pathways. Cytojournal 22, 6 (2025).","journal-title":"Cytojournal"},{"key":"30705_CR32","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.cell.2013.10.056","volume":"155","author":"W Liu","year":"2013","unstructured":"Liu, W. et al. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. Cell 155, 1581\u20131595 (2013).","journal-title":"Cell"},{"key":"30705_CR33","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1038\/s41467-019-11132-w","volume":"10","author":"M Wong","year":"2019","unstructured":"Wong, M. et al. JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. Nat. Commun. 10, 3319 (2019).","journal-title":"Nat. Commun."},{"key":"30705_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","volume":"17","author":"B Donati","year":"2018","unstructured":"Donati, B., Lorenzini, E. & Ciarrocchi, A. BRD4 and cancer: going beyond transcriptional regulation. Mol. Cancer. 17, 164 (2018).","journal-title":"Mol. Cancer"},{"key":"30705_CR35","unstructured":"Kamiya, H. et al. Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer. Br J Cancer. 202310.1038\/s41416-023-02532-3."},{"key":"30705_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12967-025-06241-8","volume":"23","author":"H Chen","year":"2025","unstructured":"Chen, H. et al. JMJD6 K375 acetylation restrains lung cancer progression by enhancing METTL14\/m6A\/SLC3A2 axis mediated cell ferroptosis. J. Transl Med. 23, 233 (2025).","journal-title":"J. Transl Med."},{"key":"30705_CR37","doi-asserted-by":"publisher","first-page":"109303","DOI":"10.1016\/j.clim.2023.109303","volume":"250","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y. et al. Interferon-\u03b12a induces CD4(+) T cell apoptosis and suppresses Th1\/Th17 responses via upregulating IRF1-mediated PDL1 expression in dendritic cells from behcet\u2019s uveitis. Clin. Immunol. 250, 109303 (2023).","journal-title":"Clin. Immunol."},{"key":"30705_CR38","doi-asserted-by":"publisher","first-page":"e718","DOI":"10.1002\/ctm2.718","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer. Clin. Transl Med. 12, e718 (2022).","journal-title":"Clin. Transl Med."},{"key":"30705_CR39","doi-asserted-by":"crossref","unstructured":"Tian, B. et al. BRD4 couples NF-\u03baB\/RelA with airway inflammation and the IRF-RIG-I amplification loop in respiratory syncytial virus infection. J Virol ; 91. (2017).","DOI":"10.1128\/JVI.00007-17"},{"key":"30705_CR40","doi-asserted-by":"publisher","first-page":"13225","DOI":"10.1038\/s41598-018-31658-1","volume":"8","author":"K Ebine","year":"2018","unstructured":"Ebine, K. et al. Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells. Sci. Rep. 8, 13225 (2018).","journal-title":"Sci. Rep."},{"key":"30705_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12964-023-01319-6","volume":"21","author":"SL Kim","year":"2023","unstructured":"Kim, S. L., Choi, H. S. & Lee, D. S. BRD4\/nuclear PD-L1\/RelB circuit is involved in the stemness of breast cancer cells. Cell. Commun. Signal. 21, 315 (2023).","journal-title":"Cell. Commun. Signal."},{"key":"30705_CR42","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore, J. E. et al. BET bromodomain Inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904\u2013917 (2011).","journal-title":"Cell"},{"key":"30705_CR43","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1038\/s41388-023-02781-9","volume":"42","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. JMJD6 in tumor-associated macrophage regulates macrophage polarization and cancer progression via STAT3\/IL-10 axis. Oncogene 42, 2737\u20132750 (2023).","journal-title":"Oncogene"},{"key":"30705_CR44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227\u2013231 (2016).","journal-title":"Science"},{"key":"30705_CR45","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0022034517712435","volume":"96","author":"LL Bu","year":"2017","unstructured":"Bu, L. L. et al. STAT3 induces immunosuppression by upregulating PD-1\/PD-L1 in HNSCC. J. Dent. Res. 96, 1027\u20131034 (2017).","journal-title":"J. Dent. Res."},{"key":"30705_CR46","first-page":"379","volume":"12","author":"MQ Liang","year":"2020","unstructured":"Liang, M. Q., Yu, F. Q. & Chen, C. C-Myc regulates PD-L1 expression in esophageal squamous cell carcinoma. Am. J. Transl Res. 12, 379\u2013388 (2020).","journal-title":"Am. J. Transl Res."},{"key":"30705_CR47","doi-asserted-by":"publisher","first-page":"9457","DOI":"10.1002\/jcp.29750","volume":"235","author":"A Jahangiri","year":"2020","unstructured":"Jahangiri, A., Dadmanesh, M. & Ghorban, K. STAT3 Inhibition reduced PD-L1 expression and enhanced antitumor immune responses. J. Cell. Physiol. 235, 9457\u20139463 (2020).","journal-title":"J. Cell. Physiol."},{"key":"30705_CR48","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","volume":"76","author":"KJ Lastwika","year":"2016","unstructured":"Lastwika, K. J. et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in Non-Small cell lung cancer. Cancer Res. 76, 227\u2013238 (2016).","journal-title":"Cancer Res."},{"key":"30705_CR49","doi-asserted-by":"publisher","first-page":"17810","DOI":"10.1038\/s41598-017-18132-0","volume":"7","author":"JW Moon","year":"2017","unstructured":"Moon, J. W. et al. IFN\u03b3 induces PD-L1 overexpression by JAK2\/STAT1\/IRF-1 signaling in EBV-positive gastric carcinoma. Sci. Rep. 7, 17810 (2017).","journal-title":"Sci. Rep."},{"key":"30705_CR50","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480\u2013489 (2011).","journal-title":"Nature"},{"key":"30705_CR51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205\u2013214 (2015).","journal-title":"Cell"},{"key":"30705_CR52","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"30705_CR53","doi-asserted-by":"publisher","first-page":"14209","DOI":"10.18632\/oncotarget.3694","volume":"6","author":"Y Tang","year":"2015","unstructured":"Tang, Y. et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 6, 14209\u201314219 (2015).","journal-title":"Oncotarget"},{"key":"30705_CR54","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jtho.2019.01.011","volume":"14","author":"A Jeanson","year":"2019","unstructured":"Jeanson, A. et al. Efficacy of immune checkpoint inhibitors in KRAS-Mutant Non-Small cell lung cancer (NSCLC). J. Thorac. Oncol. 14, 1095\u20131101 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"30705_CR55","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","volume":"17","author":"MJ Topper","year":"2020","unstructured":"Topper, M. J. et al. The emerging role of epigenetic therapeutics in immuno-oncology. Nat. Rev. Clin. Oncol. 17, 75\u201390 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"30705_CR56","unstructured":"J, B., MK, G. & CH, W. TNM Classification of Malignant Tumors, 8th Edition. (2017)."},{"key":"30705_CR57","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/carcin\/bgx139","volume":"39","author":"T Imamura","year":"2018","unstructured":"Imamura, T. et al. Overexpression of ZRF1 is related to tumor malignant potential and a poor outcome of gastric carcinoma. Carcinogenesis 39, 263\u2013271 (2018).","journal-title":"Carcinogenesis"},{"key":"30705_CR58","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1111\/cas.15342","volume":"113","author":"Y Takashima","year":"2022","unstructured":"Takashima, Y. et al. Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer. Cancer Sci. 113, 1984\u20131998 (2022).","journal-title":"Cancer Sci."},{"key":"30705_CR59","first-page":"2436","volume":"8","author":"J Kiuchi","year":"2018","unstructured":"Kiuchi, J. et al. Overexpression of YEATS4 contributes to malignant outcomes in gastric carcinoma. Am. J. Cancer Res. 8, 2436\u20132452 (2018).","journal-title":"Am. J. Cancer Res."},{"key":"30705_CR60","doi-asserted-by":"publisher","first-page":"363","DOI":"10.62347\/NZMO2658","volume":"15","author":"H Arakawa","year":"2025","unstructured":"Arakawa, H. et al. Overexpression of SHANK2 contributes malignant outcomes as a Hippo pathway regulator in gastric cancer. Am. J. Cancer Res. 15, 363\u2013374 (2025).","journal-title":"Am. J. Cancer Res."},{"key":"30705_CR61","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/carcin\/bgp116","volume":"30","author":"S Komatsu","year":"2009","unstructured":"Komatsu, S. et al. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 30, 1139\u20131146 (2009).","journal-title":"Carcinogenesis"},{"key":"30705_CR62","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1111\/j.1349-7006.2012.02407.x","volume":"103","author":"K Kashimoto","year":"2012","unstructured":"Kashimoto, K. et al. Overexpression of TRIM44 contributes to malignant outcome in gastric carcinoma. Cancer Sci. 103, 2021\u20132026 (2012).","journal-title":"Cancer Sci."},{"key":"30705_CR63","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/bjc.2013.65","volume":"108","author":"Y Nishimura","year":"2013","unstructured":"Nishimura, Y. et al. Overexpression of YWHAZ relates to tumor cell proliferation and malignant outcome of gastric carcinoma. Br. J. Cancer. 108, 1324\u20131331 (2013).","journal-title":"Br. J. Cancer"},{"key":"30705_CR64","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/bjc.2016.394","volume":"116","author":"T Ohashi","year":"2017","unstructured":"Ohashi, T. et al. Overexpression of PBK\/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma. Br. J. Cancer. 116, 218\u2013226 (2017).","journal-title":"Br. J. Cancer"},{"key":"30705_CR65","doi-asserted-by":"publisher","first-page":"84112","DOI":"10.18632\/oncotarget.21109","volume":"8","author":"K Aratani","year":"2017","unstructured":"Aratani, K. et al. Overexpression of CTEN relates to tumor malignant potential and poor outcomes of adenocarcinoma of the esophagogastric junction. Oncotarget 8, 84112\u201384122 (2017).","journal-title":"Oncotarget"},{"key":"30705_CR66","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12282-008-0032-5","volume":"15","author":"H Tsuda","year":"2008","unstructured":"Tsuda, H. Individualization of breast cancer based on histopathological features and molecular alterations. Breast Cancer. 15, 121\u2013132 (2008).","journal-title":"Breast Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30705-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30705-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30705-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T18:02:37Z","timestamp":1768154557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30705-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["30705"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-30705-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experimental methods were carried out in accordance with relevant guidelines and regulations, such as the Declaration of Helsinki. Written informed consent was obtained from all patients to use their tissue specimens and blood samples. This study was approved by the institutional review boards of Kyoto Prefectural University of Medicine (ERB-C-319-1).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"1069"}}